Kahaly G, Beyer J
Abteilung Innere Medizin, Endokrinologie und Stoffwechsel, Klinikum der Johannes-Gutenberg Universität Mainz.
Klin Wochenschr. 1988 Nov 1;66(21):1049-59. doi: 10.1007/BF01711917.
Thyroid eye disease is attributed to an autoimmune process where both cellular and humoral immunity play a role. In this report, after a short introduction dealing with immunopathogenesis of the disease, immunosuppressant therapy is discussed. Treatment with glucocorticoids (as the standard substance), nonsteroid immunosuppressants (azathioprine, cyclophosphamide, lately cyclosporin) and with the immunomodulatory substance ciamexone is reviewed. Retroorbital irradiation as a "local" immunosuppressive method and plasmapheresis are also discussed. While systemic glucocorticoids and to a lesser extent orbital radiotherapy are routinely administered for severe Graves' ophthalmopathy, nonsteroid immunosuppressants and plasmapheresis are not yet part of the established treatment of thyroid eye disease. Their use should currently remain confined to controlled studies.
甲状腺眼病归因于一种自身免疫过程,在此过程中细胞免疫和体液免疫均发挥作用。在本报告中,在简短介绍该疾病的免疫发病机制后,对免疫抑制疗法进行了讨论。回顾了使用糖皮质激素(作为标准药物)、非甾体免疫抑制剂(硫唑嘌呤、环磷酰胺,最近还有环孢素)以及免疫调节物质西阿美松的治疗情况。还讨论了作为“局部”免疫抑制方法的眶后照射和血浆置换。虽然全身糖皮质激素以及在较小程度上的眼眶放射治疗通常用于治疗重度格雷夫斯眼病,但非甾体免疫抑制剂和血浆置换尚未成为甲状腺眼病既定治疗方法的一部分。目前它们的使用应仅限于对照研究。